Powered by

-Progenics Pharmaceuticals Announces Presentation of Updated Safety and Tolerability Data for AZEDRA at the Radiological Society of North America Annual Meeting

Nov 20, 2018 - ENP Newswire

NEW YORK - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that safety and tolerability data from a pooled analysis of four open-label, Phase 1 and 2 studies of AZEDRA (iobenguane I 131) in patients with iobenguane scan positive cancers will be presented in an oral session at the upcoming Radiological Society of North America (RSNA) 2018 Annual Meeting, which wil...